Just a few years ago, the idea of at-home testing was practically antithetical to Caesar Djavaherian’s mission. The clinician and founder was laser-focused on serving people in person with his network of urgent care clinics. Fast forward to the spring of 2020, and his company — fresh off the heels of a merger with Carbon Health — was dashing to offer one of the first at-home test kits for Covid-19.
Home diagnostics have long been considered a kind of holy grail in telehealth: While a majority of virtual care can now be conducted remotely, the process of identifying a condition typically requires a physical visit. But a recent burst of activity in the sector — fueled by the pandemic and its need for rapid, remote tests — offers the potential to solve one of the industry’s thorniest last-mile problems.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.